{"name": "Regenesance",
 "permalink": "regenesance",
 "crunchbase_url": "http://www.crunchbase.com/company/regenesance",
 "homepage_url": "http://www.regenesance.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2009,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@regenesance.com",
 "phone_number": "617-418-1600",
 "description": "",
 "created_at": "Thu Dec 02 06:22:42 UTC 2010",
 "updated_at": "Fri Dec 03 19:35:02 UTC 2010",
 "overview": "\u003Cp\u003ERegenesance BV was founded in November, 2009 on ground breaking research from the Academic Medical Center (AMC) at the University of Amsterdam in the Netherlands. AMC researchers found that an innate part of the immune system (complement pathway) is activated after nerve damage to produce a lytic complex (called the membrane attack complex or MAC). Normally, the MAC attacks pathogens and helps remove tissue debris following trauma. However, AMC researchers learned that MAC can also damage nerves, particularly those attempting to regrow after injury. This work indicates that a variety of acute or chronic nervous system disorders may benefit from new therapies that strategically control MAC activation. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       63],
      "assets/images/resized/0011/2550/112550v1-max-150x150.jpg"],
     [[250,
       105],
      "assets/images/resized/0011/2550/112550v1-max-250x250.jpg"],
     [[256,
       108],
      "assets/images/resized/0011/2550/112550v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Robert",
      "last_name": "L. Buchanan",
      "permalink": "robert-l-buchanan",
      "image": null}},
   {"is_past": false,
    "title": "CSO",
    "person":
     {"first_name": "Frank",
      "last_name": "Baas",
      "permalink": "frank-baas",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [{"round_code": "seed",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020101130e6c1000ul\u0026r=Rss\u0026s=DJFVW",
    "source_description": "Dutch Specialty Pharma Co. Regenesance Closes Seed Round ",
    "raised_amount": null,
    "raised_currency_code": null,
    "funded_year": 2010,
    "funded_month": 12,
    "funded_day": 1,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Meibergdreef 45",
    "address2": "R-Noord 01-152",
    "zip_code": "1105 BA",
    "city": "Amsterdam",
    "state_code": null,
    "country_code": "NLD",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "qu\u00e1\u00bb\u00b3nh add New Milestone ",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 1,
    "source_url": "http://vnexpress.net/GL/The-gioi/",
    "source_text": null,
    "source_description": "http://vnexpress.net/GL/The-gioi/2010/12/3BA23B15/",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Regenesance",
      "permalink": "regenesance"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}